

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sessptal642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?): 2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 BRISTLEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUB
NEWS 6 Apr 22 Records from IP.com available in CAPUS, HCAPUS, and ZCAPUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FedRip) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFUL has been reloaded
NEWS 12 Jun 10 FORCE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NEFFIRST to be removed from STN
NEWS 16 Aug 08 PHARMARKETletter(PHARMARK) - new on STN
NEWS 17 Aug 08 CANCERLIT reload
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUINE)
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAP10 has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.04,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CMS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:14:25 ON 02 OCT 2002

=> file medline, cancerlit, biosis, confsci, embase, caplus, uspatfull	
COST IN U.S. DOLLARS	SINCE FILE TOTAL
FULL ESTIMATED COST	ENTRY SESSION
	0.21 0.21

FILE 'MEDLINE' ENTERED AT 12:14:51 ON 02 OCT 2002

FILE 'CANCERLIT' ENTERED AT 12:14:51 ON 02 OCT 2002

FILE 'BIOSIS' ENTERED AT 12:14:51 ON 02 OCT 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CONFSCI' ENTERED AT 12:14:51 ON 02 OCT 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 12:14:51 ON 02 OCT 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:14:51 ON 02 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFUL' ENTERED AT 12:14:51 ON 02 OCT 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s syndecan(a)4

L1 585 SYNDECAN(A) 4

=> s 11 and angiogene?

L2 29 11 AND ANGIOGENE?

=> s 11 and fibronectin?

L3 83 11 AND FIBRONECTIN?

=> s 13 and inhibit

L4 10 13 AND INHIBIT

=> s 13 and inhibit?

L5 35 13 AND INHIBIT?

=> d 12 1-29

L2 ANSWER 1 OF 29 MEDLINE

AN 2002460455 IN-PROCESS

DN 22126577 Pubmed ID: 12128069

TI A recombinant NH(2)-terminal heparin-binding domain of the adhesive

glycoprotein, thrombospondin-1, promotes endothelial tube formation and

cell survival: a possible role for syndecan-4

proteoglycan.

AU Ferrari do Outeiro-Bernstein Mariana A; Nunes Sara Santana; Andrade Ana

Carolina Magalhaes; Alves Tercia Rodrigues; Legrand Chantal; Morandi

Veronica

Departamento de Biologia Celular e Genetica, Instituto de Biologia Roberto

Alcantara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rua Sao

Francisco Xavier, 524 PHC sala 205, Maracanã, Rio de Janeiro, RJ, Brazil.

MATRIX BIOLOGY. (2002 Jun) 21 (4) 311-24.

SO Journal code: 9432592. ISSN: 0945-053X.

CY Germany: Germany, Federal Republic of
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS IN-PROCESS; NONINDEXED; Priority Journals
 ED Entered STN: 20020911
 Last Updated on STN: 20020911

 L2 ANSWER 2 OF 29 MEDLINE
 AN 2001495375 PubMed ID: 11544026
 DN 21428909
 TI Syndecan-4 and focal adhesion function.
 AU Woods A; Couchman J R
 CS Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA.. awood@cellbio.bham.uab.edu
 NC DK 54605 (NIDDK)
 SO CURRENT OPINION IN CELL BIOLOGY. (2001 Oct) 13 (5) 578-83. Ref: 57
 CY Journal code: 8913428. ISSN: 0955-0674.
 DT United States
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS General Review; (REVIEW)
 (REVIEW LITERATURE)
 ED Entered STN: 20010910
 Last Updated on STN: 20011015
 Entered Medline: 20011011

 L2 ANSWER 3 OF 29 MEDLINE
 AN 2001140784 PubMed ID: 11160142
 DN 21102376
 TI Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.
 AU Gschwendtner F; Streit M; Wilcox-Adelman S; Saoncello S; Denhez F; Detmar M; Gellera J
 CS Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
 NC CA69184 (NCI)
 SO JOURNAL OF CLINICAL INVESTIGATION. (2001 Jan) 107 (2) R9-R14.
 CY Journal code: 7802877. ISSN: 0021-9738.
 DT United States
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Abstracted Index Medicus Journals; Priority Journals
 EM 200103
 ED Entered STN: 20010404
 Last Updated on STN: 20010404
 Entered Medline: 20010308

 L2 ANSWER 4 OF 29 MEDLINE
 AN 1998444445 PubMed ID: 9771483
 DN 98444445
 TI Heparan sulphate proteoglycan expression in human primary liver tumours.
 AU Roskams T; De Vos R; David G; Van Damme B; Desmet V
 CS Laboratory for Histocchemistry, University of Leuven, Belgium.
 SO JOURNAL OF PATHOLOGY. (1998 Jul) 185 (3) 290-7.
 CY Journal code: 0204634. ISSN: 0022-3417.
 ENGLAND: United Kingdom
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals

EM 199810
 ED Entered STN: 19981029
 Last Updated on STN: 19981029
 Entered Medline: 19981019

 L2 ANSWER 5 OF 29 CANCERLIT
 AN 1998444445
 DN 98444445 PubMed ID: 9771483
 TI Heparan sulphate proteoglycan expression in human primary liver tumours.
 AU Roskams T; De Vos R; David G; Van Damme B; Desmet V
 CS Laboratory for Histocchemistry, University of Leuven, Belgium.
 SO JOURNAL OF PATHOLOGY. (1998 Jul) 185 (3) 290-7.
 CY Journal code: 0204634. ISSN: 0022-3417.
 DT ENGLAND: United Kingdom
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS MEDLINE; Priority Journals
 OS MEDLINE 1998444445
 EM 199810
 ED Entered STN: 19981118
 Last Updated on STN: 19981118

 L2 ANSWER 6 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002470155 BIOSIS
 DN PREV200200470155
 TI A recombinant NH2-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: A possible role for syndecan-4 proteoglycan.
 AU do Outeiro-Bernstein, Mariana A. Ferrari, Nunes, Sara Santana; Andrade, Ana Carolina Magalhães; Alves, Tercia Rodrigues; Legrand, Chantal; Morandi, Veronica (1)
 CS (1) Departamento de Biologia Celular e Genética, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rua São Francisco Xavier, 524, Maracanã, PHC Sala 205, Rio de Janeiro, RJ: veronica@uerj.br Brazil
 SO Matrix Biology. (June, 2002) Vol. 21, No. 4, pp. 311-324.
 http://www.elsevier.com/locate/matrix. print.
 ISSN: 0945-053X.
 DT Article
 LA English

 L2 ANSWER 7 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002428611 BIOSIS
 DN PREV200200428611
 TI Modulation of microvascular signaling by heparan sulfate matrix: Studies in syndecan-4 transgenic mice.
 AU Li, Jian; Parovian, Chohren; Li, Jiaany; Hampton, Thomas G.; Metais, Caroline; Trachenko, Eugene; Seljke, Frank W.; Simons, Michael (1)
 CS (1) Angiogenesis Research Center and Section of Cardiology, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, Lebanon, NH, 03756; Michael.Simons@dartmouth.edu USA
 SO Microvascular Research. (July, 2002) Vol. 64, No. 1, pp. 38-46.
 http://www.academypress.com/micrpath. print.
 ISSN: 0026-2862.
 DT Article
 LA English

 L2 ANSWER 8 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002263200 BIOSIS
 DN PREV200200263200
 TI Syndecan-4 dependent manner: Cross-talk between PKC isozymes.

AU Murakami, Masahiro (1); Horowitz, Arie; Simons, Michael
 CS (1) Dartmouth-Hitchcock Med Ctr, Lebanon, NH USA
 SO Circulation, (October 23, 2001) Vol. 104, No. 17 Supplement, pp. II-34.
 http://circ.ahajournals.org/. print.
 Meeting Info.: Scientific Sessions 2001 of the American Heart Association
 Anaheim, California, USA November 11-14, 2001
 ISSN: 0009-7322.
 DT Conference
 LA English
 L2 ANSWER 9 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001.83295 BIOSIS
 DN PREV200100083295
 TI Delayed wound repair and impaired angiogenesis in mice lacking
 syndecan-4.
 AU Echtermeyer, Frank; Streif, Michael; Wilcox-Adelman, Sarah; Saoncelia,
 CS Stefani; Denhez, Fabienne; Delmar, Michael; Goetlinck, Paul F. (1)
 (1) Cutaneous Biology Research Center, MGH-East, 13th Street, Building
 149, Charlestown, MA, 02129; paul.goetlinck@chrc2.mgh.harvard.edu USA
 SO Journal of Clinical Investigation, (January, 2001) Vol. 107, No. 2, pp.
 R9-R14. print.
 ISSN: 0021-9738.
 DT Article
 LA English
 SL English
 L2 ANSWER 10 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2000.304026 BIOSIS
 DN PREV200000304026
 TI Syndecan signaling in angiogenesis.
 AU Simons, Michael (1)
 CS (1) Angiogenesis Research Center, BIDMC, Harvard Medical School, Boston,
 MA USA
 SO FASEB Journal, (March 15, 2000) Vol. 14, No. 4, pp. A799. print.
 Meeting Info.: Annual Meeting of Professional Research Scientists:
 Experimental Biology 2000 San Diego, California, USA April 15-18, 2000
 Federation of American Societies for Experimental Biology
 . ISSN: 0892-6638.
 DT Conference
 LA English
 SL English
 L2 ANSWER 11 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1999.524045 BIOSIS
 DN PREV199900524045
 TI Syndecan-4 cytoplasmic domain-dependent regulation of
 endothelial cell growth.
 AU Volk, Ruediger (1); Li, Jian (1); Schwartz, Jay; Horowitz, Arie; Simons,
 Michael (1)
 CS (1) BIDMC/Harvard Med. Sch., Boston, MA USA
 SO Circulation, (Oct. 27, 1998) Vol. 98, No. 17 SUPPL., pp. 1391.
 Meeting Info.: 71st Scientific Sessions of the American Heart Association
 Dallas, Texas, USA November 8-11, 1998 The American Heart Association
 . ISSN: 0009-7322.
 DT Conference
 LA English
 L2 ANSWER 12 OF 29 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998.339438 BIOSIS
 DN PREV199800339438
 TI Heparan sulphate proteoglycan expression in human primary liver tumours.
 AU Roskams, Tania (1); De Vos, Rita; Van Damme, Guido David Boudewijn;
 Desmet, Valere
 CS (1) Lab. Histo- Cytochem., Univ. Leuven, Mindebroederstr. 23, B-3000

SO Leuven Belgium
 DT Journal of Pathology, (July, 1998) Vol. 185, No. 3, pp. 290-297.
 LA ISSN: 0022-3417.
 DT Article
 L2 ANSWER 13 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001311467 EMBASE
 TI Syndecan-4 and focal adhesion function.
 AU Woods A.; Couchman J.R.
 CS A. Woods, Department of Cell Biology, University of Alabama, Birmingham,
 AL 35294-0019, United States. awoods@cellbio.uab.edu
 SO Current Opinion in Cell Biology, (1 Oct 2001) 13/5 (578-583).
 Refs: 57
 ISSN: 0955-0674 CODEN: COCB3
 DT United Kingdom
 LA Journal: General Review
 FS 029 Clinical Biochemistry
 SL English
 L2 ANSWER 14 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001037199 EMBASE
 TI Delayed wound repair and impaired angiogenesis in mice lacking
 syndecan-4.
 AU Echtermeyer F.; Streif M.; Wilcox-Adelman S.; Saoncelia S.; Denhez F.;
 Delmar M.; Goetlinck P.F.
 CS P.F. Goetlinck, Cutaneous Biology Research Center, MGH-East, Building 149,
 13th Street, Charlestown, MA 02129, United States.
 paul.goetlinck@chrc2.mgh.harvard.edu
 SO Journal of Clinical Investigation, (2001) 107/2 (R9-R14).
 Refs: 25
 ISSN: 0021-9738 CODEN: JCINAO
 DT United States
 LA Journal: Article
 FS 013 Dermatology and Venerology
 SL 029 Clinical Biochemistry
 LA English
 L2 ANSWER 15 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 1998233281 EMBASE
 TI Heparan sulphate proteoglycan expression in human primary liver tumours.
 AU Roskams T.; De Vos R.; David G.; Van Damme B.; Desmet V.
 CS Dr. T. Roskams, Lab. for Histo- and Cytochemistry, University of Leuven,
 Minderebroederstraat 12, B-3000 Leuven, Belgium
 SO Journal of Pathology, (1998) 185/3 (290-297).
 Refs: 35
 ISSN: 0022-3417 CODEN: JPTLAS
 DT United Kingdom
 LA Journal: Article
 FS 005 General Pathology and Pathological Anatomy
 SL 016 Cancer
 LA 048 Gastroenterology
 SL English
 L2 ANSWER 16 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 97336357 EMBASE
 DN 1997336357
 TI Macrophage-dependent regulation of syndecan gene expression.
 AU Li J.; Brown L.F.; Laham R.J.; Volk R.; Simons M.
 CS Dr. M. Simons, Cardiovascular Division, Beth Israel Deaconess Medical
 Center, 330 Brookline Ave, Boston, MA 02215, United States.

SO	Birmingham, AL, 35294-0019, USA																																																																																													
BI	Current Opinion in Cell Biology (2001), 13(5), 578-583																																																																																													
CO	CODEN: COCBEJ, ISSN: 0955-0674																																																																																													
PB	Elsevier Science Ltd.																																																																																													
PT	Journal; General Review																																																																																													
LA	English																																																																																													
RE CNT	57																																																																																													
THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD																																																																																														
ALL CITATIONS AVAILABLE IN THE RE FORMAT																																																																																														
L2	ANSWER 20 OF 29 CAPLUS COPYRIGHT 2002 ACS																																																																																													
AN	2001:416975																																																																																													
DN	135:37179																																																																																													
TI	Proteoglycans and pharmaceutical compositions comprising them																																																																																													
IN	Xayon, Avner																																																																																													
PA	Teda Research and Development Co. Ltd., Israel																																																																																													
SO	PCT Int. Appl., 40 pp. CODEN: PIXX2																																																																																													
DT	Patent LA English																																																																																													
FAN	CNT 1																																																																																													
<table border="1"> <thead> <tr> <th>PATENT NO.</th> <th>KIND</th> <th>DATE</th> <th>APPLICATION NO.</th> <th>DATE</th> </tr> </thead> <tbody> <tr> <td>PI WO 2001040267</td> <td>A2</td> <td>200106071</td> <td>WO 2000-11821</td> <td>20001205</td> </tr> <tr> <td>MO 2001040267</td> <td>A3</td> <td>200200711</td> <td></td> <td></td> </tr> <tr> <td colspan="5">M:</td> </tr> <tr> <td>AE, AC, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN,</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>CR, CC, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, HR,</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT,</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, N2, NZ, PL, PT, RO, RU,</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>YU, ZA, ZW, AM, AZ, AY, KG, KZ, MD, RU, TJ, TW</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>RN: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, T2, TG, UM</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>BE, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NW, PT, SE, TR, BF,</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>DJ, DK, EG, ES, FI, FR, GB, GR, IE, IT, LU, MC, NI, PD, PG,</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>EP 1237922</td> <td>A2</td> <td>20020911</td> <td>EP 2000-979926</td> <td>20001205</td> </tr> <tr> <td>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>IE, SI, ST, LV, FI, MK, CY, AL, TR</td> <td></td><td></td><td></td><td></td> </tr> <tr> <td>PRAI II, 1999-133316</td> <td>A</td> <td>19991205</td> <td></td><td></td> </tr> <tr> <td>MO 2000-11821</td> <td>M</td> <td>20001205</td> <td></td><td></td> </tr> </tbody> </table>					PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	PI WO 2001040267	A2	200106071	WO 2000-11821	20001205	MO 2001040267	A3	200200711			M:					AE, AC, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN,					CR, CC, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, HR,					HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT,					LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, N2, NZ, PL, PT, RO, RU,					SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,					YU, ZA, ZW, AM, AZ, AY, KG, KZ, MD, RU, TJ, TW					RN: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, T2, TG, UM					BE, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NW, PT, SE, TR, BF,					DJ, DK, EG, ES, FI, FR, GB, GR, IE, IT, LU, MC, NI, PD, PG,					EP 1237922	A2	20020911	EP 2000-979926	20001205	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,					IE, SI, ST, LV, FI, MK, CY, AL, TR					PRAI II, 1999-133316	A	19991205			MO 2000-11821	M	20001205		
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE																																																																																										
PI WO 2001040267	A2	200106071	WO 2000-11821	20001205																																																																																										
MO 2001040267	A3	200200711																																																																																												
M:																																																																																														
AE, AC, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN,																																																																																														
CR, CC, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, HR,																																																																																														
HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT,																																																																																														
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, N2, NZ, PL, PT, RO, RU,																																																																																														
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,																																																																																														
YU, ZA, ZW, AM, AZ, AY, KG, KZ, MD, RU, TJ, TW																																																																																														
RN: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, T2, TG, UM																																																																																														
BE, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NW, PT, SE, TR, BF,																																																																																														
DJ, DK, EG, ES, FI, FR, GB, GR, IE, IT, LU, MC, NI, PD, PG,																																																																																														
EP 1237922	A2	20020911	EP 2000-979926	20001205																																																																																										
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,																																																																																														
IE, SI, ST, LV, FI, MK, CY, AL, TR																																																																																														
PRAI II, 1999-133316	A	19991205																																																																																												
MO 2000-11821	M	20001205																																																																																												
L2	ANSWER 21 OF 29 CAPLUS COPYRIGHT 2002 ACS																																																																																													
AN	2001:48429																																																																																													
DN	134:176534																																																																																													
TI	Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4																																																																																													
AU	Echtemeyer, Frank; Streif, Michael; Wilcox-Adelman, Sarah; Saoncelia, Stephanie; Demhez, Fabienne; Dermat, Michael; Goerlinc, Paul F.																																																																																													
CS	Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA																																																																																													
SO	Journal of Clinical Investigation (2001), 107(2), R9-R14 CODEN: JCIHNO; ISSN: 0021-9738																																																																																													
PB	American Society for Clinical Investigation																																																																																													
DT	Journal																																																																																													
LA	English																																																																																													
RE CNT	25																																																																																													
THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD																																																																																														
ALL CITATIONS AVAILABLE IN THE RE FORMAT																																																																																														
L2	ANSWER 22 OF 29 CAPLUS COPYRIGHT 2002 ACS																																																																																													
AN	2000:335257																																																																																													
DN	133:823																																																																																													
TI	Stimulation of angiotensin via syndecan-4																																																																																													
IN	Cytoplasmic domain signaling pathway																																																																																													
PA	Nimons, Michael; Horowitz, Arie																																																																																													
SO	Beth Israel Deaconess Medical Center, USA PCT Int. Appl., 73 pp.																																																																																													
RE CNT	50																																																																																													

CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000027416	A1	20000518	WO 1999-US26647	19991110
W: AU, CA, JP				
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1131081	A1	20010912	EP 1999-962741	19991110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI US 1998-190976	A	19981112		
WO 1999-US26647	W	19991110		
RE CNT 6				
THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L2 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:175824 CAPLUS
 DN 132:217982
 TI Stimulation of angiogenesis via enhanced endothelial expression of chimeric heparan sulfate-binding proteins
 IN Simons, Michael; Volk, Rudiger; Horowitz, Arle
 PA Beth Israel Deaconess Medical Center, USA
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000014103	A1	20000316	WO 1999-US18665	19990818
W: AU, CA, JP				
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9956794	A1	20000327	AU 1999-56794	19990818
EP 1112283	A1	20010704	EP 1999-943760	19990818
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI US 1998-145916	A	19980902		
WO 1999-US18665	W	19990818		
RE CNT 3				
THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L2 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2002 ACS
 AN 1996:357168 CAPLUS
 DN 155:26311
 TI Syndecan (syndecan expression-inducers) mediate modulation of tissue repair
 IN Gallo, Richard L.; Bernfield, Merton
 PA Children's Medical Center Corporation, USA
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9609322	A2	19960328	WO 1995-US12080	19950922
WO 9609322	A3	19960328		
W: AU, CA, JP, KR				
RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5654273	A	19970805	US 1994-310722	19940922

AU 9538228 A1 19960409 AU 1995-38228 19950922
 US 5863897 A 19990126
 PRAI US 1994-310722 19940922
 WO 1995-US12080 19950922

L2 ANSWER 25 OF 29 USPATFULL
 AN 2002:112871 USPATFULL
 TI Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
 IN Franco, Wayne P.; Rocky Hill, CT, UNITED STATES
 PI US 2002058612 A1 20020516
 AI US 2001-828330 A1 20010406 (9)
 PRAI US 2000-195624P 20000406 (60)
 DT Utility
 FS APPLICATION

LN CNT 2636
 INCL INCLM: 514/002.000
 INCLS: 424/043.000
 NCLM: 514/002.000
 NCL NCLM: 424/043.000
 IC [7]
 ICM: A61K09-04
 ICS: A61K038-18

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 26 OF 29 USPATFULL
 AN 2002:92068 USPATFULL
 TI Methods of modulating wound healing and angiogenesis
 IN Goetnick, Paul F., Boston, MA, UNITED STATES
 PI US 2002048585 A1 20020425
 AI US 2001-900288 A1 20010706 (9)
 PRAI US 2000-216247P 20000706 (60)
 DT Utility
 FS APPLICATION

LN CNT 1486
 INCL INCLM: 424/155.100
 INCLS: 514/012.000; 514/044.000
 NCLM: 424/155.100
 NCL NCLM: 514/012.000; 514/044.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K039-395; A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 27 OF 29 USPATFULL
 AN 2002:22428 USPATFULL
 TI Neoglycan anticancer agents and uses thereof
 IN Sanderson, Ralph D.; Maumelle, AR, UNITED STATES
 PI US 2002013264 A1 20020131
 AI US 2001-921032 A1 20010802 (9)
 PRAI Continuation-in-part of Ser. No. US 2000-479139, filed on 7 Jan 2000, PENDING
 DT Utility
 FS APPLICATION

LN CNT 1334
 INCL INCLM: 514/002.000
 INCLS: 514/054.000; 514/056.000; 514/059.000
 NCLM: 514/002.000
 NCL NCLM: 514/054.000; 514/056.000; 514/059.000
 IC [7]
 ICM: A61K038-00

ICS: A61K031-728; A61K031-727; A61K031-726; A61K031-721; A61K031-737
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 28 OF 29 USPTFULL
AN 1999:12906 USPTFULL
TI Synchron mediated modulation of tissue repair
IN Gallo, Richard L., Natick, MA, United States
PA Benfield, Merton, Boston, MA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5863897 19990126
AI US 1996-728333 19961010 (8)
RUI Continuation of Ser. No. US 1994-310722, filed on 22 Sep 1994, now patented. Pat. No. US 5654273
DT Utility
FS Granted
LN.CNT 666
INCL INCLM: 514/012.000
INCL INCLM: 514/008.000
NCL INCLM: 514/012.000
NCLM: 514/008.000
IC [6]
ICM: A61K038-00
ICS: A61K038-02; C07K005-00; C07K007-00
EXF 514/12: 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 29 OF 29 USPTFULL
AN 97:68443 USPTFULL
TI Synchron mediated modulation of tissue repair
IN Gallo, Richard L., Natick, MA, United States
PA Benfield, Merton, Boston, MA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5654273 19970805
AI US 1994-310722 19940922 (8)
DT Utility
FS Granted
LN.CNT 748
INCL INCLM: 514/012.000
INCL INCLM: 514/008.000; 530/324.000
NCL INCLM: 514/012.000
NCLM: 514/008.000; 530/324.000
IC [6]
ICM: A61K038-00
ICS: C07K005-00; C07K007-00; C07K017-00
EXF 514/12: 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his
(FILE 'HOME' ENTERED AT 12:14:25 ON 02 OCT 2002)
FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPTFULL'
ENTERED AT 12:14:51 ON 02 OCT 2002
L1 585 S SYNDICAN(A)4
L2 29 S L1 AND ANGIOGENE?
L3 83 S L1 AND FIBRONECTIN?
L4 10 S L3 AND INHIBIT
L5 35 S L3 AND INHIBIT?
=> d 14 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 2000:666752 CAPLUS
DN 133:232876
TI Methods of modulating cell attachment and migration using a modulator of
IN Syndecan-4 ectodomain binding with a counterligand
PA Goetnick, Paul
PA The General Hospital Corporation, USA
SO PCT Int. Appl., 61 pp.
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2000055181 A1 20000921 WO 2000-US6740 20000315
W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
PRAI US 1999-124396P P 19990315
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 USPTFULL
AN 2002:221323 USPTFULL
TI Molecular toxicology modeling
IN Mendrick, Donna L., Mount Airy, MD, UNITED STATES
Porter, Mark W., Germantown, MD, UNITED STATES
Johnson, Kory R., Bethesda, MD, UNITED STATES
Castle, Arthur L., Washington, DC, UNITED STATES
Elashoff, Michael R., Germantown, MD, UNITED STATES
PI US 2002119462 A1 20020829
AI US 2001-917800
PRAI US 2000-222040P 20000731 (9)
US 2000-244880P 20001102 (60)
US 2001-280029P 20010511 (60)
US 2001-280645P 20010515 (60)
US 2001-292316P 20010522 (60)
US 2001-295798P 20010606 (60)
US 2001-297457P 20010613 (60)
US 2001-298884P 20010619 (60)
US 2001-303459P 20010709 (60)
DT Utility
FS APPLICATION
LN.CNT 9801
INCL INCLM: 435/006.000
INCL INCLM: 702/020.000
NCL INCLM: 435/006.000
NCLM: 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 10 USPTFULL
AN 2002:206116 USPTFULL
TI Toxicant-induced differential gene expression
IN Reidmaat-Olson, John F., Montclair, NJ, UNITED STATES
PI US 2002110808 A1 20020815
AI US 2000-489220 A1 20000121 (9)
DT Utility
FS APPLICATION
LN.CNT 5161
INCL INCLM: 435/006.000
INCL INCLM: 435/091.200; 536/023.100

NCL NCLM: 435/006.000
NCLS: 435/091.200; 536/023.100

IC [7]
ICM: C120001-68
ICS: C07H021-02; C07H021-04; C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPTAFULL
AN 2002:92068 USPTAFULL
TI Methods of modulating wound healing and angiogenesis
IN Goetlinck, Paul F., Boston, MA, UNITED STATES
PI US 2002048585 AI 20020425
AI US 2001-900288 AI 20010706 (9)
PRAI US 2000-216247P 20000706 (60)
DT Utility
FS APPLICATION
LN.CNT 1486
INCL INCLM: 424/155.100
INCLS: 514/012.000; 514/044.000
NCL NCLM: 424/155.100
NCLS: 514/012.000; 514/044.000

IC [7]
ICM: A61K048-00
ICS: A61K039-395; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPTAFULL
AN 2002:22107 USPTAFULL
TI POLYPEPTIDES WITH A4 INTEGRIN SUBUNIT RELATED ACTIVITY
IN MCCARTHY, JAMES B., MINNEAPOLIS, MN, UNITED STATES
FURCHT, LEO T., MINNEAPOLIS, MN, UNITED STATES
IIDA, JOEL, SHOREVIEW, MN, UNITED STATES
PA Regents of the University of Minnesota, Minneapolis, MN (U.S. corporation)
PI US 2002012942 AI 20020131
AI US 1998-10714 AI 19980122 (9)
DT Utility
FS APPLICATION
LN.CNT 1102
INCL INCLM: 435/007.100
INCLS: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
427/002.100; 623/001.100
NCL NCLM: 435/007.100
NCLS: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
427/002.100; 623/001.100

IC [7]
ICM: A61K038-00
ICS: A61K038-04; C07K017-00; C07K016-00; C07K014-00; C07K005-00;
C07K004-00; C07K002-00; C07K007-00; C12M001-00; G01N033-53; A61L002-00;
A61F002-06; B05D003-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPTAFULL
AN 2000:18280 USPTAFULL
TI Nucleic acid sequence of senescence associated gene
IN Funk, Walter, Hayward, CA, United States
PA Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
PI US 6025194 20000215
AI US 1997-974180 19971119 (8)
DT Utility
FS Granted
LN.CNT 4667
INCL INCLM: 435/320.100
INCLS: 536/023.100; 536/023.500; 536/024.100; 435/320.100; 435/325.000

NCL NCLM: 435/320.100
NCLS: 435/325.000; 536/023.100; 536/023.500; 536/024.100

IC [7]
ICM: C07H021-04
ICS: C12N015-63; C12N015-85; C12N015-11
536/23.5; 536/23.1; 536/24.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 10 USPTAFULL
AN 1999:12906 USPTAFULL
TI Synuclein mediated modulation of tissue repair
IN Gallo, Richard L., Natick, MA, United States
Bernfield, Merton, Boston, MA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5863897 19990126
AI US 1996-728333 19961010 (8)
RLI Continuation of Ser. No. US 1994-310722, filed on 22 Sep 1994, now patented, Pat. No. US 5654273
DT Utility
FS Granted
LN.CNT 666
INCL INCLM: 514/012.000
INCLS: 514/008.000
NCL NCLM: 514/012.000
NCLS: 514/008.000

IC [6]
ICM: A61K038-00
ICS: A61K038-02; C07K005-00; C07K007-00
514/12; 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 USPTAFULL
AN 1998:15925 USPTAFULL
TI Suppression of tumor cell growth by syndecan-1 ectodomain
IN Jalkanen, Markku, Espoo, Finland
Mali, Markku, Saito, Finland
PA Biote Therapies Ltd., Turku, Finland (non-U.S. corporation)
PI US 5851993 19981222
AI US 1995-488199 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-258862, filed on 13 Jun 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1585
INCL INCLM: 514/012.000
INCLS: 514/008.000; 514/021.000; 530/395.000
NCL NCLM: 514/012.000
NCLS: 514/008.000; 514/021.000; 530/395.000

IC [6]
ICM: A61K038-17
ICS: A61K038-16; C07K014-47; C07K014-705
514/8; 514/12; 514/21; 436/64; 530/380; 530/395; 530/808; 530/827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 10 USPTAFULL
AN 97:68443 USPTAFULL
TI Synuclein mediated modulation of tissue repair
IN Gallo, Richard L., Natick, MA, United States
Bernfield, Merton, Boston, MA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5654273 19970805
AI US 1994-310722 19940922 (8)

DT Utility
FS Granted
LN.CNT 748
INCL INCLM: 514/012.000
NCL INCLM: 514/008.000; 530/324.000
NCLM: 514/012.000
NCLS: 514/008.000; 530/324.000
IC [6]
ICM: A61K038-00
ICS: C07K005-00; C07K007-00; C07K017-00
EXF 514/12; 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 10 USPATFILL
AN 967785 USPATFILL
TI Construction and use of synthetic constructs encoding syndecan
IN Saunders, Scott, Boston, MA, United States
Bernfield, Merton, Boston, MA, United States
Kato, Masato, Boston, MA, United States
PA The Board of Trustees of the Ireland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5486599 19960123
AI US 1993-78683 19930617 (8)
RLI Continuation-in-part of Ser. No. US 1991-757654, filed on 6 Sep 1991, now abandoned And a continuation-in-part of Ser. No. US 1992-856869, filed on 24 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-746797, filed on 12 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-311585, filed on 29 Mar 1989, now abandoned
DT Utility
FS Granted
LN.CNT 3939
INCL INCLM: 530/395.000
NCL INCLM: 536/023.500; 435/069.700; 435/252.300; 435/320.100; 536/023.400; 536/023.500; 935/010.000; 935/047.000; 935/050.000; 935/070.000
NCLM: 530/395.000
NCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400; 536/023.500
IC [6]
ICM: C07K014-435
ICS: C07K019-00; C12N015-12; C12N015-62
EXF 536/23.4; 530/395; 530/350; 435/69.7; 435/69.1; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his
(FILE 'HOME' ENTERED AT 12:14:25 ON 02 OCT 2002)
FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPATFILL'
ENTERED AT 12:14:51 ON 02 OCT 2002
L1 585 S SYNDSCAN(A)4
L2 29 S L1 AND ANGIOGENE?
L3 83 S L1 AND FIBRORECTIN?
L4 10 S L3 AND INHIBIT
L5 35 S L3 AND INHIBIT?
=> d 15 1-35
L5 ANSWER 1 OF 35 MEDLINE
AN 2002460455 IN-PROCESS
DN 22126577 Pubmed ID: 12128069

TI A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4
AU Ferrari do Outeiro-Bernstein Mariana A; Nunes Sara Santana; Andrade Ana Carolina Magalhães; Alves Tercia Rodrigues; Legrand Chantal; Morandi Veronica
CS Departamento de Biologia Celular e Genética, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rua São Francisco Xavier, 524 PHLG sala 205, Maracana, Rio de Janeiro, RJ, Brazil.
SO MATRIX BIOLOGY. (2002 Jun) 21 (4) 311-24.
Journal code: 9432592. ISSN: 0945-053X.
CY Germany; Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20020911
Last Updated on STN: 20020911

L5 ANSWER 2 OF 35 MEDLINE
AN 2002448107 IN-PROCESS
DN 22194361 Pubmed ID: 12087088
TI Syndecan-4 modulates focal adhesion kinase phosphorylation.
AU Wilcox-Adelman Sarah A; Denhez Fabienne; Goettinck Paul F
CS Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129.
SO JOURNAL OF BIOLOGICAL CHEMISTRY. (2002 Sep 6) 277 (36) 32970-7.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20020904
Last Updated on STN: 20020904

L5 ANSWER 3 OF 35 MEDLINE
AN 2001689481 MEDLINE
DN 21587766 Pubmed ID: 11731446
TI Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation.
AU Huang W; Chiquet-Ehrismann R; Moyano J V; Garcia-Pardo A; Orend G
CS Friedrich Miescher Institute for Biomedical Research, 4056 Basel, Switzerland.
SO CANCER RESEARCH. (2001 Dec 1) 61 (23) 8586-94.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200201
ED Entered STN: 20011212
Last Updated on STN: 20020125
Entered Medline: 20020103

L5 ANSWER 4 OF 35 MEDLINE
AN 2001551530 MEDLINE
DN 21482060 Pubmed ID: 11598898
TI PR-39 coordinates changes in vascular smooth muscle cell adhesive strength and locomotion by modulating cell surface heparan sulfate-matrix interactions.
AU Chon J H; Houston M M; Xu C; Chaikof E L
CS School of Chemical Engineering, Georgia Institute of Technology, Atlanta,

Georgia, USA.
HL60963 (NHLBI)
NC JOURNAL OF CELLULAR PHYSIOLOGY, (2001 Nov) 189 (2) 133-43.
SO Journal code: 0050222. ISSN: 0021-9541.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200110
ED Entered STN: 20011015
Last Updated on STN: 20011029
Entered Medline: 20011025

L5 ANSWER 5 OF 35 MEDLINE
AN 1999178970
DN 99178970 PubMed ID: 10077592
TI *syndecan-4* signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers.
AU Saoncelle S; Echtermeyer F; Demhez F; Nowlen J K; Mosher D F; Robinson S D; Hyman R O; Goetinck P F
CS Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
NC HD-22016 (NICHHD)
HL21644 (NHLBI)

SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. (1999 Mar 16) 96 (6) 2805-10.
CY Journal code: 7505876. ISSN: 0027-8424.
DT United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199905
ED Entered STN: 19990601
Last Updated on STN: 20000303
Entered Medline: 19990520

L5 ANSWER 6 OF 35 CANCERLIT
AN 2002097321
DN 21587766 PubMed ID: 11731446
TI Interference of tenascin-C with *syndecan-4* binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation.
AU Huang W; Chiquet-Ehrismann R; Moyano J V; Garcia-Pardo A; Orend G
CS Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland.
SO CANCER RESEARCH. (2001 Dec 1) 61 (23) 8586-94.
CY Journal code: 2984705R. ISSN: 0008-5472.
DT United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE: Priority Journals
OS MEDLINE 2001689481
EM 200201
ED Entered STN: 20020726
Last Updated on STN: 20020726

L5 ANSWER 7 OF 35 CANCERLIT
AN 2002081050
DN 21482060 PubMed ID: 11598898
TI PR-39 coordinates changes in vascular smooth muscle cell adhesive strength and locomotion by modulating cell surface heparan sulfate-matrix interactions.

AU Chon J H; Houston M W; Xu C; Chaikof E L
CS School of Chemical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
NC HL60863 (NHLBI)
SO JOURNAL OF CELLULAR PHYSIOLOGY, (2001 Nov) 189 (2) 133-43.
CY Journal code: 0050222. ISSN: 0021-9541.
DT United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE: Priority Journals
OS MEDLINE 2001551530
EM 200110
ED Entered STN: 20020726
Last Updated on STN: 20020726

L5 ANSWER 8 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:470155 BIOSIS
DN PREV200200470155
TI A recombinant NH2-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: A possible role for *syndecan-4* proteoglycan.
AU do Oureiro-Bernstein, Mariana A. Ferrari; Nunes, Sara Santana; Andrade, Ana Carolina Magalhães; Alves, Tercia Rodrigues; Degrand, Chantal; Morandi, Veronica (1)
CS (1) Departamento de Biologia Celular e Genética, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rua São Francisco Xavier, 524, Maracanã, PHC Sala 205, Rio de Janeiro, RJ: veronica@uerj.br Brazil
SO Matrix Biology. (June, 2002) Vol. 21, No. 4, pp. 311-324.
http://www.elsevier.com/locate/matrix. print.
ISSN: 0945-053X.

DT English
LA English

L5 ANSWER 9 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:38297 BIOSIS
DN PREV20020038297
TI Interference of tenascin-C with *syndecan-4* binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation.
AU Huang, Wentao; Chiquet-Ehrismann, Ruth; Moyano, Jose V.; Garcia-Pardo, Angeles; Orend, Gertrud (1)
CS (1) Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058, Basel: goren@fmi.ch Switzerland
SO Cancer Research. (December 1, 2001) Vol. 61, No. 23, pp. 8586-8594.
http://cancerres.aacrjournals.org/. print.
ISSN: 0008-5472.

DT English
LA English

L5 ANSWER 10 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:512824 BIOSIS
DN PREV200100512824
TI PR-39 coordinates changes in vascular smooth muscle cell adhesive strength and locomotion by modulating cell surface heparan sulfate-matrix interactions.
AU Chon, John H.; Houston, Michelle M.; Xu, Chengpei; Chaikof, Elliot L. (1)
CS (1) Emory University, 1639 Pierce Drive, Room 5105, Atlanta, GA, 30322: echaiko@emory.edu USA
SO Journal of Cellular Physiology. (November, 2001) Vol. 189, No. 2, pp. 133-143. print.
ISSN: 0021-9541.
DT Article

LA English
SL English

L5 ANSWER 11 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:218581 BIOSIS
DN PREVIEW9900218581

TI Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers.

AU Saoncelia, Stefania; Echtermeyer, Frank; Denhez, Fabienne; Nowlen, Julie K.; Mosher, Deane F.; Robinson, Stephen D.; Hynes, Richard O.; Goetinck, Paul F. (1)

CS (1) Cutaneous Biology Research Center, 13th Street, MGH-East, Building 149, Charlestown, MA, 02129 USA
SO Proceedings of the National Academy of Sciences of the United States of America, (March 16, 1999) Vol. 96, No. 6, pp. 2805-2810.
ISSN: 0027-8424.

DT Article
LA English
SL English

L5 ANSWER 12 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2001431465 EMBASE
TI Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation.

AU Huang W.; Chiquet-Ehrismann R.; Moyano J.V.; Garcia-Pardo A.; Orend G. G.; Orend, F.; Miescher Inst. For Biomed. Res., Maulbeeralstrasse 66, 4058 Basel, Switzerland. goren@iml.ch
SO Cancer Research, (1 Dec 2001) 61/23 (8586-8594).
Refs: 56
ISSN: 0008-5472 CODEN: CUREA8

CY United States
DT Journal: Article
FS 016 Cancer
LA English
SL English

L5 ANSWER 13 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2001356736 EMBASE
TI PR-39 coordinates changes in vascular smooth muscle cell adhesive strength and locomotion by modulating cell surface heparan sulfate-matrix interactions.

AU Chon J.H.; Houston M.M.; Xu C.; Chaikof E.L.
SO E.L. Chaikof, Emory University, 1639 Pierce Drive, Atlanta, GA 30322, United States. echaikof@emory.edu (2001) 189/2 (133-143).
Refs: 49
ISSN: 0021-9541 CODEN: JCLLAX

CY United States
DT Journal: Article
FS 002 Physiology
LA English
SL English

L5 ANSWER 14 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1999114471 EMBASE
TI Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers.

AU Saoncelia S.; Echtermeyer F.; Denhez F.; Nowlen J.K.; Mosher D.F.; Robinson S.D.; Hynes R.O.; Goetinck P.F.
SO P.F. Goetinck, Cutaneous Biology Research Center, MGH-East, Building 149,

SO 13th Street, Charlestown, MA 02129, United States.
pgoetinck@crb.mgh.harvard.edu
Proceedings of the National Academy of Sciences of the United States of America, (1999) 96/6 (2805-2810).
Refs: 33
ISSN: 0027-8424 CODEN: PNASA6

CY United States
DT Journal: Conference Article
FS 029 Clinical Biochemistry
LA English
SL English

L5 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 2002:720593 CAPLUS
TI Syndecan-4 Modulates Focal Adhesion Kinase Phosphorylation

AU Wilcox-Adelman, Sarah A.; Denhez, Fabienne; Goetinck, Paul F.
CS Massachusetts General Hospital, Cutaneous Biology Research Center, Harvard Medical School, Charlestown, MA, 02129, USA
SO Journal of Biological Chemistry (2002), 277(36), 32970-32977
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English

L5 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 2002:575295 CAPLUS
DN 137118777

TI Marker proteins and genes for human colon cancer, methods and compositions for their diagnostic, prognostic, and therapeutic uses

IN Schlegel, Robert; Berger, Allison
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2

DT Patent
LA English
SL English

PI PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2002059376 A1 20020801 WO 2002-US2188 20020123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM

RW: GM, KE, LS, MW, MZ, SD, ST, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-26320P P 20010123
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 2002:548089 CAPLUS
TI A recombinant NH2-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan

AU Ferrari do Outeiro-Bernstein, Mariana A.; Nunes, Sara Santana; Andrade, Ana Carolina Magalhães; Alves, Tercia Rodrigues; Legrand, Chantal; Morandi, Veronica

CS Instituto de Biologia Roberto Alcântara Gomes, Departamento de Biologia

PRAI US 1999-124396P P 19990315
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2002 ACS

AN 1999-124396P CAPLUS
DN 12:31744
TI Gene probes used for genetic profiling in healthcare screening and planning
IN Roberts, Gareth Wyn
PA Genosic Pharma Ltd., UK
SO PCT Int. Appl., 745 pp.
CODEN: PIXXD2

DT Patent
LA English

PAN.CNT 2

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 964627 A2 19991216 WO 1999-GB1780 19990604

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI GB 1998-12099 A 19980606

GB 1998-13291 A 19980620
GB 1998-13611 A 19980624
GB 1998-13835 A 19980627
GB 1998-14110 A 19980701
GB 1998-14580 A 19980707
GB 1998-15438 A 19980716
GB 1998-15574 A 19980718
GB 1998-15576 A 19980718
GB 1998-16085 A 19980724
GB 1998-16086 A 19980724
GB 1998-16921 A 19980805
GB 1998-17097 A 19980807
GB 1998-17200 A 19980808
GB 1998-17632 A 19980814
GB 1998-17943 A 19980819

L5 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2002 ACS

AN 1999-1795993 CAPLUS

DN 12:31743
TI Gene probes used for genetic profiling in healthcare screening and planning

IN Roberts, Gareth Wyn
PA Genosic Pharma Limited, UK
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2

DT Patent
LA English

PAN.CNT 2

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 964626 A2 19991216 WO 1999-GB1779 19990604
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9941586 A1 19991230 AU 1999-41586 19990604
AU 9941587 A1 19991230 AU 1999-41587 19990604
GB 2339200 A1 20000119 GB 1999-12914 19990604
GB 2339200 B2 20010912
EP 1084273 A1 20010321 EP 1999-925207 19990604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, MC, PT, IE, FI

PRAI GB 1998-12098 A 19980606

GB 1998-28289 A 19981223
GB 1998-16086 A 19980724
GB 1998-16921 A 19980805
GB 1998-17097 A 19980807
GB 1998-17200 A 19980808
GB 1998-17632 A 19980814
GB 1998-17943 A 19980819
WO 1999-GB1779 W 19990604

L5 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2002 ACS

AN 1999-198699 CAPLUS

DN 130:350264
TI Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers
AU Saoncelle, Stefania; Echtermeyer, Frank; Denhez, Fabienne; Nowlen, Julie K.; Mosher, Deane F.; Robinson, Stephen D.; Hynes, Richard O.; Goettlinc, Paul F.

CS Cutaneous Biology Research Center, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, 02129, USA
SO Proceedings of the National Academy of Sciences of the United States of America (1999), 96(6) 2805-2810
CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

RE.CNT 33

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 35 CAPLUS

AN 2002-221323 USPATFULT

TI Molecular toxicology modeling

IN Mendrick, Donna L.; Mount Atty, MD, UNITED STATES

Porter, Mark W.; Germantown, MD, UNITED STATES

Johnson, Kory R.; Bethesda, MD, UNITED STATES

Castle, Arthur L.; Washington, DC, UNITED STATES

Elschoff, Michael R.; Germantown, MD, UNITED STATES

PI US 200219462 A1 20020829

US 2001-917800 A1 20020829

US 2000-222040P 20000731 (60)

US 2000-244880P 20001102 (60)

US 2001-290029P 20010511 (60)

US 2001-290645P 20010515 (60)

US 2001-292336P 20010522 (60)

US 2001-295798P 20010606 (60)

US 2001-297457P 20010613 (60)

US 2001-298884P 20010619 (60)

US 2001-303459P 20010709 (60)

DT Utility

FS Application

LN.CNT 9801

INCL INCLM: 435/006.000
 INCLM: 702/020.000
 NCLM: 435/006.000
 NCLM: 702/020.000
 IC [7]
 ICM: C120001-68
 ICS: G06F019-00; G01N033-48; G01N033-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 35 USPTFULL
 AN 2002:206116 USPTFULL
 TI Toxicant-induced differential gene expression
 IN Rejzhaat-Olison, John F., Montclair, NJ, UNITED STATES
 PI US 2002110808 AI 20020815
 AI US 2000-489220 AI 20000121 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 5161
 INCL INCLM: 435/006.000
 INCLM: 435/091.200; 536/023.100
 NCLM: 435/006.000
 NCLM: 435/091.200; 536/023.100
 IC [7]
 ICM: C120001-68
 ICS: C07H021-02; C07H021-04; C12P019-34
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 35 USPTFULL
 AN 2002:92068 USPTFULL
 TI Methods of modulating wound healing and angiogenesis
 IN Goelink, Paul F., Boston, MA, UNITED STATES
 PI US 2002048585 AI 20020425
 AI US 2001-900288 AI 20010706 (9)
 PRAI US 2000-216247P 20000706 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1466
 INCL INCLM: 424/155.100
 INCLM: 514/012.000; 514/044.000
 NCLM: 424/155.100
 NCLM: 514/012.000; 514/044.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K039-395; A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 35 USPTFULL
 AN 2002:22107 USPTFULL
 TI POLYPEPTIDES WITH A4 INTEGRIN SUBUNIT RELATED ACTIVITY
 IN MCCARTHY, JAMES B., MINNEAPOLIS, MN, UNITED STATES
 FURCHT, LEO T., MINNEAPOLIS, MN, UNITED STATES
 IIDA, JOEL, SHOREVIEW, MN, UNITED STATES
 PA Regents of the University of Minnesota, Minneapolis, MN (U.S. Corporation)
 PI US 2002012842 AI 20020131
 AI US 1998-10714 AI 19980122 (9)
 DT Utility
 FS APPLICATION
 LN.CNT 1102
 INCL INCLM: 435/007.100
 INCLM: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
 427/002.100; 623/001.100
 NCLM: 435/007.100
 NCLM: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;

IC [7]
 427/002.100; 623/001.100
 ICM: A61K038-00
 ICS: A61K038-04; C07K017-00; C07K016-00; C07K014-00; C07K005-00;
 C07K004-00; C07K002-00; C07K007-00; C12M001-00; G01N033-53; A61L002-00;
 A61F002-06; B05D003-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 35 USPTFULL
 AN 2002:16917 USPTFULL
 TI Growth stimulation of biological cells and tissue by electromagnetic
 IN fields and uses thereof
 WOLF, David A., Houston, TX, UNITED STATES
 PA Goodwin, Thomas J., Friendswood, TX, UNITED STATES
 PI US 2002009797 AI 20020124
 AI US 2001-798854 AI 20010228 (9)
 RLI Division of Ser. No. US 2000-587028, filed on 2 Jun 2000, ABANDONED
 DT Utility
 FS APPLICATION
 LN.CNT 1200
 INCL INCLM: 435/289.100
 INCLM: 435/298.200; 435/173.800
 NCLM: 435/289.100
 NCLM: 435/298.200; 435/173.800
 IC [7]
 ICM: C12M003-00
 ICS: C12N013-00

L5 ANSWER 31 OF 35 USPTFULL
 AN 2000:18280 USPTFULL
 TI Nucleic acid sequence of senescence associated gene
 IN Funk, Walter, Hayward, CA, United States
 PA Genon Corporation, Menlo Park, CA, United States (U.S. Corporation)
 PI US 6025194 20000215
 AI US 1997-974180 19971119 (8)
 DT Utility
 FS Granted
 LN.CNT 4667
 INCL INCLM: 435/320.100
 INCLM: 536/023.100; 536/023.500; 536/024.100; 435/320.100; 435/325.000
 NCLM: 435/320.100
 NCLM: 435/325.000; 536/023.100; 536/023.500; 536/024.100
 IC [7]
 ICM: C07H021-04
 ICS: C12N015-63; C12N015-85; C12N015-11
 ICS: 536/23.5; 536/23.1; 536/24.1; 435/320.1; 435/325
 EXF 536/23.5; 536/23.1; 536/24.1; 435/320.1; 435/325
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 35 USPTFULL
 AN 1999:12906 USPTFULL
 TI Synuclein mediated modulation of tissue repair
 IN Gallo, Richard L., Natick, MA, United States
 Bernfield, Merton, Boston, MA, United States
 PA Children's Medical Center Corporation, Boston, MA, United States (U.S. Corporation)
 PI US 5863897 19990126
 AI US 1996-728333 19961010 (8)
 RLI Continuation of Ser. No. US 1994-310722, filed on 22 Sep 1994, now
 DT patented, Pat. No. US 5654273
 FS Utility
 LN.CNT 666
 INCL INCLM: 514/012.000

INCL: 514/008.000
NCL: 514/012.000
NCLM: 514/008.000
IC [6]
ICM: A61K038-00
ICS: A61K038-02; C07K005-00; C07K007-00
EXF 514/12; 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 35 USPATFULL
AN 1998:159925 USPATFULL
TI Suppression of tumor cell growth by syndecan-1 ectodomain
IN Jalkanen, Markku, Finland
PA Maki, Marku, Sato, Finland
PA Biotie Therapies Ltd., Turku, Finland (non-U.S. corporation)
PI US 5651993 19981222
AI US 1995-488199 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-258862, filed on 13 Jun 1994,
now abandoned
DT Utility
FS Granted
IN.CNT 1585
INCL INCLM: 514/012.000
NCL INCLM: 514/008.000; 514/021.000; 530/395.000
NCLM: 514/012.000
NCLM: 514/008.000; 514/021.000; 530/395.000
IC [6]
ICM: A61K038-17
ICS: A61K038-16; C07K014-47; C07K014-705
EXF 514/8; 514/12; 514/21; 436/64; 530/380; 530/395; 530/808; 530/827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 35 USPATFULL
AN 97:68443 USPATFULL
TI Syndecan mediated modulation of tissue repair
IN Gallo, Richard L., Natick, MA, United States
PA Bernfield, Metton, Boston, MA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5654273 19970805
AI US 1994-310722 19940922 (8)
DT Utility
FS Granted
IN.CNT 748
INCL INCLM: 514/012.000
NCL INCLM: 514/008.000; 530/324.000
NCLM: 514/012.000
NCLM: 514/008.000; 530/324.000
IC [6]
ICM: A61K038-00
ICS: C07K005-00; C07K007-00; C07K017-00
EXF 514/12; 514/8; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 35 USPATFULL
AN 96:7785 USPATFULL
TI Construction and use of synthetic constructs encoding syndecan
IN Saunders, Scott, Boston, MA, United States
PA Bernfield, Metton, Boston, MA, United States
PA Kato, Masato, Boston, MA, United States
PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)

PI US 5486599 19960123
AI US 1993-78683 19930617 (8)
RLI Continuation-in-part of Ser. No. US 1991-757654, filed on 6 Sep 1991,
now abandoned And a continuation-in-part of Ser. No. US 1992-856869,
filed on 24 Mar 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1991-746797, filed on 12 Aug 1991, now abandoned which is a
continuation-in-part of Ser. No. US 1989-331585, filed on 29 Mar 1989,
now abandoned
DT Utility
FS Granted
IN.CNT 3939
INCL INCLM: 530/395.000
NCL INCLM: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400;
NCLM: 536/023.500; 935/010.000; 935/047.000; 935/050.000; 935/070.000
NCLM: 536/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400;
NCLM: 536/023.500
IC [6]
ICM: C07K014-435
ICS: C07K019-00; C12N015-12; C12N015-62
EXF 536/23.4; 530/395; 530/350; 435/69.7; 435/69.1; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 11 and cancer?
L7 37 L1 AND CANCER?

=> d 1-37

L7 ANSWER 1 OF 37 MEDLINE
AN 2001234892 Pubmed ID: 11251555
DN 21149694
TI Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers.
AU Lundqvist K; Schmidchen A
CS Department of Dermatology, Biomedical Center, B14, Lund University, Tornavägen S-221 85 Lund, Sweden.
SO BRITISH JOURNAL OF DERMATOLOGY (2001 Feb) 144 (2) 254-9.
Journal code: 0004041. ISSN: 0007-0963.

CY England: United Kingdom
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200105
ED Entered STN: 20010517
Last Updated on STN: 20010517
Entered Medline: 20010503

L7 ANSWER 2 OF 37 MEDLINE
AN 2001139297 Pubmed ID: 11169953
DN 21101228
TI Soluble and matrix-associated heparan sulfate proteoglycans increase expression of erb-B2 and erb-B3 in colon cancer cell lines.
AU Zivbel I; Brill S; Halpern Z; Moskovitz S; Yaron A; Papa M
CS Liver Metastasis Research Group, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.. isab@casnic.health.gov.il
SO INTERNATIONAL JOURNAL OF CANCER (2001 Feb 1) 91 (3) 316-21.
Journal code: 0042124. ISSN: 0020-7126.

CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200103
ED Entered STN: 20010404
Last Updated on STN: 20010404
Entered Medline: 20010308

L7 ANSWER 3 OF 37 CANCERLIT
AN 2001101228 Pubmed ID: 11169953
DN 21101228
TI Soluble and matrix-associated heparan sulfate proteoglycans increase expression of erb-B2 and erb-B3 in colon cancer cell lines.
AU Zivbel I; Brill S; Halpern Z; Moskovitz S; Yaron A; Papa M
CS Liver Metastasis Research Group, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.. isab@casnic.health.gov.il
SO INTERNATIONAL JOURNAL OF CANCER (2001 Feb 1) 91 (3) 316-21.
Journal code: 0042124. ISSN: 0020-7126.

CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS MEDLINE 2001139297
EM 200103
ED Entered STN: 20010515
Last Updated on STN: 20010515

L7 ANSWER 4 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:409836 BIOSIS

DN PREV200200409836
TI Gene expression profiles of organ-specific metastases in breast cancer.
AU Lee, Hyerim (1); Smith, Jeffrey W. (1)
CS (1) The Burnham Institute, La Jolla, CA USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2002) Vol. 43, pp. 905. print.
Meeting, info.: 93rd Annual Meeting of the American Association for Cancer Research San Francisco, California, USA April 06-10, 2002
ISSN: 0197-016X.

DT Conference
LA English

L7 ANSWER 5 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:260469 BIOSIS
DN PREV200200260469
TI Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements.
AU Brockstedt, Ulrika; Dobra, Katalin; Nurminen, Mervi; Hjerppe, Anders (1)
CS (1) Department of IMPI, Division of Pathology, Karolinska Institutet, Huddinge University Hospital, F46, S-14186, Huddinge:
anders.hjerppe@pathlab.hs.sll.se Sweden
AU Anders, Hjerppe@pathlab.hs.sll.se Sweden
SO Experimental Cell Research, (April 1, 2002) Vol. 274, No. 2, pp. 235-245.
http://www.academipress.com/ectr. print.
ISSN: 0014-4827.

DT Article
LA English

L7 ANSWER 6 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:111679 BIOSIS
DN PREV200200111679
TI Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas.
AU Mundhenke, Christoph; Meyer, Kristy; Drew, Sally; Friedl, Andreas (1)
CS (1) Department of Pathology and Laboratory Medicine, Clinical Sciences Center, 600 Highland Ave., R4-850, Madison, WI, 52792-8550:
afriedl@facstaff.wisc.edu USA
SO American Journal of Pathology, (January, 2002) Vol. 160, No. 1, pp. 185-194. http://ajp.amjpathol.org/. print.
ISSN: 0002-9440.

DT Article
LA English

L7 ANSWER 7 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:152884 BIOSIS
DN PREV200100152884
TI Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers.
AU Lundqvist, K.; Schmidchen, A. (1)
CS (1) Department of Dermatology and Department of Cell and Molecular Biology, Lund University, Tornavägen, Biomedical Center, B14, S-221 85, Lund: artur.schmidchen@derm.lu.se Sweden
SO British Journal of Dermatology, (February, 2001) Vol. 144, No. 2, pp. 254-259. print.
ISSN: 0007-0963.

DT Article
LA English
SL English

L7 ANSWER 8 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:81626 BIOSIS
DN PREV20010081626
TI Heparan sulfate proteoglycan expression in breast carcinomas and its impact on FGF-2 signaling.

- AU Mundhenke, C. (1); Maass, N.; Meyer, K. (1); Drew, S. (1); Friedl, A. (1)
 CS (1) Dept. of Pathology, University of Wisconsin, Madison, WI USA
 SO Breast Cancer Research and Treatment, (November, 2000) Vol. 64, No. 1, pp.
 115. Print.
 Meeting Info.: 23rd Annual San Antonio Breast Cancer Symposium San
 Antonio, Texas, USA December 06-09, 2000
 ISSN: 0167-6606.
 DT Conference
 LA English
 SL English
- L7 ANSWER 9 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001.69174 BIOSIS
 DN PREV200100069174
 TI Soluble and matrix-associated heparan sulfate proteoglycans increase
 expression of erb-B2 and erb-B3 in colon cancer cell lines.
 AU Zviibel, Isabel (1); Brill, Shlomo; Halpern, Zami; Moskovitz, Sharon;
 Yavon, Avner; Papa, Moshe
 CS (1) Liver Metastasis Research Group, Gastroenterology Institute, Tel Aviv
 Sourasky Medical Center, Weizmann 6, Tel Aviv; isab@tasmc.health.gov.il
 SO Israel
 International Journal of Cancer, (1 February, 2001) Vol. 91, No. 3, pp.
 316-321. Print.
 ISSN: 0020-7136.
 DT Article
 LA English
 SL English
- L7 ANSWER 10 OF 37 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2000.363289 BIOSIS
 DN PREV200000363289
 TI Altered patterns of heparan sulphate proteoglycan expression in human
 epithelial ovarian cancer.
 AU Davies, E. J. (1); McGown, A. (1); Shanks, J.; David, G.; Gallagher, J.
 T.; Jayson, G.
 CS (1) Department of Drug Development and Imaging, Paterson Institute for
 Cancer Research, Manchester UK
 SO British Journal of Cancer, (July, 2000) Vol. 83, No. Supplement 1, pp. 29.
 Print.
 Meeting Info.: Meeting of the British Cancer Research Brighton, UK July
 09-12, 2000
 ISSN: 0007-0920.
 DT Conference
 LA English
 SL English
- L7 ANSWER 11 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001431465 EMBASE
 TI Interference of tenascin-C with syndecan-4 binding to
 fibronectin blocks cell adhesion and stimulates tumor cell proliferation.
 AU Huang W.; Chiquet-Ehrismann R.; Moyano J.V.; Garcia-Parro A.; Orend G.
 G. Orend, F. Miescher Inst. for Biomed. Res., Maulbeerstrasse 66, 4058
 Basel, Switzerland; goren@fmi.ch
 SO Cancer Research, (1 Dec 2001) 61/23 (8586-8594).
 Refs: 56
 ISSN: 0008-5472 CODEN: CRRBAS
 DT United States
 LA English
 SL English
- L7 ANSWER 12 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001082395 EMBASE
- TI Immunohistochemical studies on proteoglycan expression in normal skin and
 chronic ulcers.
 AU Lundqvist K.; Schmidtchen A.
 CS A. Schmidtchen, Department of Dermatology, Biomedical Center, Lund
 University, Tomteavägen, S-221 85 Lund, Sweden.
 arthur.schmidtchen@derm.lu.se
 SO British Journal of Dermatology, (2001) 144/2 (254-259).
 Refs: 23
 ISSN: 0007-0963 CODEN: BJDEAZ
 DT United Kingdom
 LA English
 SL English
- L7 ANSWER 13 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001021696 EMBASE
 TI Soluble and matrix-associated heparan sulfate proteoglycans increase
 expression of erb-b2 and erb-b3 in colon cancer cell lines.
 AU Zviibel I.; Brill S.; Halpern Z.; Moskovitz S.; Yavon A.; Papa M.
 I. Zviibel, Liver Metastasis Research Group, Gastroenterology Institute,
 Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
 isab@tasmc.health.gov.il
 SO International Journal of Cancer, (1 Feb 2001) 91/3 (316-321).
 Refs: 25
 ISSN: 0020-7136 CODEN: IJCNAM
 DT United States
 LA English
 SL English
- L7 ANSWER 14 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2000253987 EMBASE
 TI Differentiation of mesothelioma cells is influenced by the expression of
 proteoglycans.
 AU Dobra K.; Andang M.; Syrokov A.; Karamanos N.K.; Hjerpe A.
 A. Hjerpe, Department of IMPI, Division of Pathology, Karolinska
 Institutet, S-14186 Stockholm, Sweden. anders.hjerpe@pathlab.hs.sll.se
 SO Experimental Cell Research, (10 Jul 2000) 258/1 (12-22).
 Refs: 44
 ISSN: 0014-4827 CODEN: ECREAL
 DT United States
 LA English
 SL English
- L7 ANSWER 15 OF 37 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 1998365945 EMBASE
 TI Syndecan-1 expression in malignant mesothelioma: Correlation with cell
 differentiation, mit expression, and clinical outcome.
 AU Kumar-Singh S.; Jacobs W.; Dhane K.; Weyn B.; Bogers J.; Weyler J.; Van
 Marck E.
 CS Prof. E. Van Marck, Laboratory of Pathology, University of Antwerp,
 Universiteitsplein 1, B-2610 Antwerp, Belgium.
 eric.van.marck@uia.ac.be
 SO Journal of Pathology, (1998) 186/3 (300-305).
 Refs: 30
 ISSN: 0022-3417 CODEN: JPTLAS
 DT United Kingdom

T1 Transcription analysis of fibroblast cells immediate-early after human
 cytomegalovirus infection
 AU Kenzelmann, Marc; Muhlemann, Kathrin
 CS Institute of Medical Microbiology, University of Bern, Bern, 3010, Switz.
 SO Journal of Molecular Microbiology (2000), 304(5), 741-751
 PB CODEN: JMOBAK; ISSN: 0022-2836
 DT Academic Press
 LA English
 RE CNT 51
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
 L7 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:666752 CAPLUS
 DN 133:232876
 TI Methods of modulating cell attachment and migration using a modulator of
 IN syndecan-4 ectodomain binding with a counterligand
 PA Goetinck, Paul
 SO The General Hospital Corporation, USA
 PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 RE CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 P1 WO 200005181 A1 20000921 WO 2000-US6740 20000315
 W: CA, JP
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE
 PRAI US 1999-124396P P 19990315
 RE CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L7 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:324878 CAPLUS
 DN 128:318018
 TI Construction of transgenic mice expressing a syndecan 1 gene in regions of
 IN hypothalamus for wt. regulation and therapy
 PA Bernfield, Merton; Reizes, Ofer
 SO Children's Medical Center Corp., USA
 PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 RE CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 P1 WO 9820121 A1 19980514 WO 1997-US20003 19971106
 W: AL, AU, BA, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP,
 KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO,
 SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 CN, ML, MR, NE, SN, TD, TG
 AU 9852437 A1 19980529 AU 1998-52437 19971106
 EP 94267 A1 19990922 EP 1997-947327 19971106
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 US 6284729 B1 20010904 US 1998-73623 19980506
 PRAI US 1996-30758P P 19961106
 US 1997-965356 A1 19971106
 WO 1997-US20003 W 19971106

L7 ANSWER 24 OF 37 USPATFULL
 AN 2002:238813 USPATFULL
 TI Identification of disease predictive nucleic acids
 AU Becker, David J.; Encinitas, CA, United States
 IN Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S.
 PA corporation)
 PI US 6451524 B1 20020917
 AI US 1998-200355 19981125 (9)
 DT Utility
 FS GRANTED
 LN CNT 1214
 INCL INCLM: 435/006.000
 INCLS: 536/023.100; 536/024.310
 NCLM: 435/006.000
 NCLS: 536/023.100; 536/024.310
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04
 EXF 435/6; 435/375; 536/23.1; 536/24.31
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L7 ANSWER 25 OF 37 USPATFULL
 AN 2002:221323 USPATFULL
 TI Molecular toxicology modeling
 AU Mendrick, Donna L.; Mount Airy, MD, UNITED STATES
 IN Porter, Mark W.; Germantown, MD, UNITED STATES
 AU Johnson, Kory R.; Bethesda, MD, UNITED STATES
 AU Castle, Arthur L.; Washington, DC, UNITED STATES
 AU Elashoff, Michael R.; Germantown, MD, UNITED STATES
 PI US 2002119462 A1 20020829
 PRAI US 2001-917800 A1 20010731 (9)
 US 2000-222040P 20000731 (60)
 US 2000-244880P 20001102 (60)
 US 2001-290029P 20010511 (60)
 US 2001-290645P 20010515 (60)
 US 2001-292336P 20010522 (60)
 US 2001-295798P 20010606 (60)
 US 2001-297457P 20010613 (60)
 US 2001-298884P 20010619 (60)
 US 2001-303459P 20010709 (60)
 DT Utility
 FS APPLICATION
 INCL INCLM: 435/006.000
 INCLS: 702/020.000
 NCLM: 435/006.000
 NCLS: 702/020.000
 IC [7]
 ICM: C12Q001-68
 ICS: G06F019-00; G01N033-48; G01N033-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L7 ANSWER 26 OF 37 USPATFULL
 AN 2002:164420 USPATFULL
 TI Compositions and methods for treating viral infections
 AU Gelsinger, Frank B.; Shreveport, LA, UNITED STATES
 IN Probe International Inc., Shreveport, LA, UNITED STATES (U.S.
 PA corporation)
 PI US 2002086034 A1 20020704
 AI US 2001-985581 A1 20011105 (9)
 RLI Division of Ser. No. US 2000-677554, filed on 2 Oct 2000, PATENTED
 Division of Ser. No. US 2000-482612, filed on 14 Jan 2000, PATENTED
 Division of Ser. No. US 1997-948782, filed on 10 Oct 1997, PATENTED

PRAI US 1996-28194P 19961010 (60)
 DT UTILITY
 FS APPLICATION
 LN CNT 3907
 INCL INCLM: 424/208.100 530/300.000; 435/005.000; 435/006.000; 435/007.100;
 INCLM: 424/188.100; 530/388.350; 530/324.000; 530/325.000; 530/326.000;
 NCLM: 424/208.100 530/389.400
 NCLM: 424/208.100 530/389.400
 NCLM: 424/188.100; 530/300.000; 435/005.000; 435/006.000; 435/007.100;
 NCLM: 424/188.100; 530/388.350; 530/324.000; 530/325.000; 530/326.000;
 NCLM: 424/208.100 530/389.400
 IC [7]
 ICM: C120001-70
 ICS: G01N003-53; C07K002-00; C07K004-00; C120001-68; A61K039-21;
 C12N005-16; C12P021-08; C12N005-06; C07K014-00; C07K016-00; A61K038-04;
 A61K038-00; C07K005-00; C07K007-00; C07K017-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 27 OF 37 USPATFULT
 TI Methods of use of fibroblast growth factor, vascular endothelial growth
 factor and related proteins in the treatment of acute and chronic heart
 disease
 IN Franco, Wayne P., Rocky Hill, CT, UNITED STATES
 PI US 2002058612 A1 20020516
 AI US 2001-828330 A1 20010406 (9)
 PRAI US 2000-195624P 20000406 (60)
 DT UTILITY
 FS APPLICATION
 LN CNT 2636
 INCL INCLM: 514/002.000
 INCLM: 424/043.000
 NCLM: 514/002.000
 NCLM: 424/043.000
 IC [7]
 ICM: A61L009-04
 ICS: A61K038-18
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 28 OF 37 USPATFULT
 TI Methods of modulating wound healing and angiogenesis
 IN Goelink, Paul F., Boston, MA, UNITED STATES
 PI US 2002046585 A1 20020425
 AI US 2001-900288 A1 20010706 (9)
 PRAI US 2000-216247P 20000706 (60)
 DT UTILITY
 FS APPLICATION
 LN CNT 1486
 INCL INCLM: 424/155.100
 INCLM: 514/012.000; 514/044.000
 NCLM: 424/155.100
 NCLM: 514/012.000; 514/044.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K039-395; A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 29 OF 37 USPATFULT
 TI Neoglycan anticancer agents and uses thereof
 IN Sanderson, Ralph D., Maumelle, AR, UNITED STATES
 Pumphrey, Carla Y., Conway, AR, UNITED STATES

PI US 2002013264 A1 20020131
 AI US 2001-921032 A1 20010802 (9)
 RLI Continuation-in-part of Ser. No. US 2000-479139, filed on 7 Jan 2000.
 PENDING
 PRAI US 1999-115053P 19990108 (60)
 DT UTILITY
 FS APPLICATION
 LN CNT 1334
 INCL INCLM: 514/002.000
 INCLM: 514/054.000; 514/056.000; 514/059.000
 NCLM: 514/002.000
 NCLM: 514/054.000; 514/056.000; 514/059.000
 IC [7]
 ICM: A61K038-00
 ICS: A61K031-728; A61K031-727; A61K031-726; A61K031-721; A61K031-737
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 30 OF 37 USPATFULT
 TI POLYPEPTIDES WITH A4 INTEGRIN SUBUNIT RELATED ACTIVITY
 IN MCCARTHY, JAMES B., MINNEAPOLIS, MN, UNITED STATES
 FURCH, LEO T., MINNEAPOLIS, MN, UNITED STATES
 IIDA, JOYI, SHOREVIEW, MN, UNITED STATES
 Regents of the University of Minnesota, Minneapolis, MN (U.S. Corporation)
 PI US 200201942 A1 20020131
 AI US 1998-10714 A1 19980122 (9)
 DT UTILITY
 FS APPLICATION
 LN CNT 1102
 INCL INCLM: 435/007.100
 INCLM: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
 NCLM: 435/007.100
 NCLM: 514/012.000; 530/300.000; 530/328.000; 530/387.100; 435/283.100;
 NCLM: 427/002.100; 623/001.100
 IC [7]
 ICM: A61K038-00
 ICS: A61K038-04; C07K017-00; C07K016-00; C07K014-00; C07K005-00;
 C07K004-00; C07K002-00; C07K007-00; C12M001-00; G01N033-53; A61L002-00;
 A61P002-06; B05D003-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 31 OF 37 USPATFULT
 TI Growth stimulation of biological cells and tissue by electromagnetic
 fields and uses thereof
 IN Wolf, David A., Houston, TX, UNITED STATES
 Goodwin, Thomas J., Friendswood, TX, UNITED STATES
 National Aeronautics & Space Administration (U.S. Corporation)
 PI US 2002009797 A1 20020124
 AI US 2001-798854 A1 20010228 (9)
 PRAI US 2000-587028, filed on 2 Jun 2000, ABANDONED
 DT UTILITY
 FS APPLICATION
 LN CNT 1200
 INCL INCLM: 435/289.100
 INCLM: 435/298.200; 435/173.800
 NCLM: 435/289.100
 NCLM: 435/298.200; 435/173.800
 IC [7]
 ICM: C12M003-00
 ICS: C12N013-00

L7 ANSWER 32 OF 37 USPTAFULL
 AN 2002:930 USPTAFULL
 TI Compositions and methods for treating viral infections
 IN Gelder, Frank B., Shreveport, LA, United States
 PA Probe International Inc., Shreveport, LA, United States (U.S. corporation)
 PI US 6335017 B1 20020101
 AI US 2000-67754 20001002 (9)
 RLI Division of Ser. No. US 2000-482612, filed on 14 Jan 2000, now patented, Pat. No. US 6258599 Division of Ser. No. US 1997-948782, filed on 10 Oct 1997, now patented, Pat. No. US 6043347
 PRAI US 1996-28194P 19961010 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3075
 INCL INCLM: 424/208.100
 INCL INCLM: 424/188.100; 530/300.000
 NCL NCLM: 424/208.100
 NCLM: 424/188.100; 530/300.000
 IC [7]
 ICM: A61K039-21
 ICS: A61K038-00
 EXF 424/188.1; 424/208.1; 530/300
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 33 OF 37 USPTAFULL
 AN 2001:107684 USPTAFULL
 TI Compositions and methods for treating viral infections
 IN Gelder, Frank B., Shreveport, LA, United States
 PA Probe International Inc., Shreveport, LA, United States (U.S. corporation)
 PI US 6258599 B1 20010710
 AI US 2000-482612 20000114 (9)
 RLI Division of Ser. No. US 1997-948782, filed on 10 Oct 1997
 PRAI US 1996-28194P 19961010 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3062
 INCL INCLM: 435/339.100
 INCL INCLM: 435/005.000; 435/006.000; 435/007.100; 530/388.350; 530/324.000; 530/325.000; 530/326.000; 530/389.400
 NCL NCLM: 435/339.100
 NCLM: 435/005.000; 435/006.000; 435/007.100; 530/324.000; 530/325.000; 530/326.000; 530/388.350; 530/389.400
 IC [7]
 ICM: C12N005-16
 ICS: C12N001-70; C12N001-68; C07K016-00; A61K038-00
 EXF 435/51; 435/6; 435/7.1; 435/339.1; 530/388.35; 530/324; 530/325; 530/326; 530/389.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 34 OF 37 USPTAFULL
 AN 2000:37903 USPTAFULL
 TI Compositions and methods for treating viral infections
 IN Gelder, Frank B., Shreveport, LA, United States
 PA Probe International Inc., Shreveport LA, United States (U.S. corporation)
 PI US 6043347 20000328
 AI US 1997-946782 19971010 (8)
 PRAI US 1996-28194P 19961010 (60)
 DT Utility
 FS Granted
 LN.CNT 3192
 INCL INCLM: 530/388.350

NCL INCLM: 435/005.000; 530/324.000; 530/325.000; 530/326.000; 530/389.400
 NCLM: 530/388.350
 NCLM: 435/005.000; 530/324.000; 530/325.000; 530/326.000; 530/389.400
 IC [7]
 ICM: C07K016-00
 ICS: C12N001-70; A61K038-00
 EXF 530/388.35; 530/324; 530/325; 530/326; 530/389.4; 435/5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 35 OF 37 USPTAFULL
 AN 2000:18280 USPTAFULL
 TI Nucleic acid sequence of senescence associated gene
 IN Funk, Walter, Hayward, CA, United States
 PA Genon Corporation, Menlo Park, CA, United States (U.S. corporation)
 PI US 6025194 20000215
 AI US 1997-974180 19971119 (8)
 DT Utility
 FS Granted
 LN.CNT 4667
 INCL INCLM: 435/320.100
 INCL INCLM: 536/023.100; 536/023.500; 536/024.100; 435/320.100; 435/325.000
 NCL NCLM: 435/320.100
 NCLM: 435/325.000; 536/023.100; 536/023.500; 536/024.100
 IC [7]
 ICM: C07H021-04
 ICS: C12N015-63; C12N015-85; C12N015-11
 EXF 536/23.5; 536/23.1; 536/24.1; 435/320.1; 435/325
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 36 OF 37 USPTAFULL
 AN 1998:159925 USPTAFULL
 TI Suppression of tumor cell growth by syndecan-1 ectodomain
 IN Jalkanen, Markku, Pilsanietti, Finland
 PA Maki, Marku, Salo, Finland
 PRAI US 5851993 19981222
 PI US 1995-488199 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1994-258862, filed on 13 Jun 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1585
 INCL INCLM: 514/012.000
 INCL INCLM: 514/008.000; 514/021.000; 530/395.000
 NCL NCLM: 514/012.000
 NCLM: 514/008.000; 514/021.000; 530/395.000
 IC [6]
 ICM: A61K038-17
 ICS: A61K038-16; C07K014-47; C07K014-705
 EXF 514/8; 514/12; 514/21; 436/64; 530/380; 530/395; 530/808; 530/827
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 37 OF 37 USPTAFULL
 AN 96:7785 USPTAFULL
 TI Construction and use of synthetic constructs encoding syndecan
 IN Saunders, Scott, Boston, MA, United States
 PA Bernfield, Merton, Boston, MA, United States
 PA Kato, Masato, Boston, MA, United States
 PA The Board of Trustees of the Ireland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
 PRAI US 5486599 19960123
 PI US 1993-78683 19930617 (8)

RII Continuation-in-part of Ser. No. US 1991-757654, filed on 6 Sep 1991,
now abandoned And a continuation-in-part of Ser. No. US 1992-856869,
filed on 24 Mar 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1991-746797, filed on 12 Aug 1991, now abandoned which is a
continuation-in-part of Ser. No. US 1989-331585, filed on 29 Mar 1989,
now abandoned

DT Utility
PS Granted
IN.CNT 3939
INCL INCLM: 530/395.000
INCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400;
536/023.500; 935/010.000; 935/047.000; 935/050.000; 935/070.000
NCLM: 530/395.000
NCL NCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400;
536/023.500
IC [6]
ICM: C07K014-435
ICG: C07K019-00; C12N015-12; C12N015-62
EXF 536/23.4; 530/395; 530/350; 435/69.7; 435/69.1; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.